Recombinant Alexa Fluor® 647 Anti-Cytokeratin 14 antibody [EP1612Y] (ab192056)
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Alexa Fluor® 647 Rabbit monoclonal [EP1612Y] to Cytokeratin 14
- Suitable for: ICC/IF
- Knockout validated
- Reacts with: Human
- Conjugation: Alexa Fluor® 647. Ex: 652nm, Em: 668nm
Related conjugates and formulations
Overview
-
Product name
Alexa Fluor® 647 Anti-Cytokeratin 14 antibody [EP1612Y]
See all Cytokeratin 14 primary antibodies -
Description
Alexa Fluor® 647 Rabbit monoclonal [EP1612Y] to Cytokeratin 14 -
Host species
Rabbit -
Conjugation
Alexa Fluor® 647. Ex: 652nm, Em: 668nm -
Tested applications
Suitable for: ICC/IFmore details -
Species reactivity
Reacts with: Human
Does not react with: Mouse, Rat -
Immunogen
Synthetic peptide. This information is proprietary to Abcam and/or its suppliers.
-
Positive control
- ICC/IF: A431 cells.
-
General notes
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Alexa Fluor® is a registered trademark of Molecular Probes, Inc, a Thermo Fisher Scientific Company. The Alexa Fluor® dye included in this product is provided under an intellectual property license from Life Technologies Corporation. As this product contains the Alexa Fluor® dye, the purchase of this product conveys to the buyer the non-transferable right to use the purchased product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). As this product contains the Alexa Fluor® dye the sale of this product is expressly conditioned on the buyer not using the product or its components, or any materials made using the product or its components, in any activity to generate revenue, which may include, but is not limited to use of the product or its components: in manufacturing; (ii) to provide a service, information, or data in return for payment (iii) for therapeutic, diagnostic or prophylactic purposes; or (iv) for resale, regardless of whether they are sold for use in research. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, 5781 Van Allen Way, Carlsbad, CA 92008 USA or outlicensing@thermofisher.com.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C. Avoid freeze / thaw cycle. Store In the Dark. -
Storage buffer
pH: 7.40
Preservative: 0.02% Sodium azide
Constituents: PBS, 30% Glycerol (glycerin, glycerine), 1% BSA -
Concentration information loading...
-
Purity
Protein A purified -
Clonality
Monoclonal -
Clone number
EP1612Y -
Isotype
IgG -
Research areas
Associated products
-
Alternative Versions
- Alexa Fluor® 488 Anti-Cytokeratin 14 antibody [EP1612Y] (ab192055)
- PE Anti-Cytokeratin 14 antibody [EP1612Y] (ab210414)
- Alexa Fluor® 555 Anti-Cytokeratin 14 antibody [EP1612Y] (ab214391)
- Anti-Cytokeratin 14 antibody [EP1612Y] - BSA and Azide free (ab243907)
- Anti-Cytokeratin 14 antibody [EP1612Y] (ab51054)
-
Isotype control
-
KO cell lines
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab192056 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
ICC/IF |
1/100.
Signal can be observed in cells fixed with MeOH or PFA. |
Notes |
---|
ICC/IF
1/100. Signal can be observed in cells fixed with MeOH or PFA. |
Target
-
Function
The nonhelical tail domain is involved in promoting KRT5-KRT14 filaments to self-organize into large bundles and enhances the mechanical properties involved in resilience of keratin intermediate filaments in vitro. -
Tissue specificity
Detected in the basal layer, lowered within the more apically located layers specifically in the stratum spinosum, stratum granulosum but is not detected in stratum corneum. Strongly expressed in the outer root sheath of anagen follicles but not in the germinative matrix, inner root sheath or hair. Found in keratinocytes surrounding the club hair during telogen. -
Involvement in disease
Defects in KRT14 are a cause of epidermolysis bullosa simplex Dowling-Meara type (DM-EBS) [MIM:131760]. DM-EBS is a severe form of intraepidermal epidermolysis bullosa characterized by generalized herpetiform blistering, milia formation, dystrophic nails, and mucous membrane involvement.
Defects in KRT14 are a cause of epidermolysis bullosa simplex Weber-Cockayne type (WC-EBS) [MIM:131800]. WC-EBS is a form of intraepidermal epidermolysis bullosa characterized by blistering limited to palmar and plantar areas of the skin.
Defects in KRT14 are a cause of epidermolysis bullosa simplex Koebner type (K-EBS) [MIM:131900]. K-EBS is a form of intraepidermal epidermolysis bullosa characterized by generalized skin blistering. The phenotype is not fundamentally distinct from the Dowling-Meara type, although it is less severe.
Defects in KRT14 are the cause of epidermolysis bullosa simplex autosomal recessive (AREBS) [MIM:601001]. AREBS is an intraepidermal epidermolysis bullosa characterized by localized blistering on the dorsal, lateral and plantar surfaces of the feet.
Defects in KRT14 are the cause of Naegeli-Franceschetti-Jadassohn syndrome (NFJS) [MIM:161000]; also known as Naegeli syndrome. NFJS is a rare autosomal dominant form of ectodermal dysplasia. The cardinal features are absence of dermatoglyphics (fingerprints), reticular cutaneous hyperpigmentation (starting at about the age of 2 years without a preceding inflammatory stage), palmoplantar keratoderma, hypohidrosis with diminished sweat gland function and discomfort provoked by heat, nail dystrophy, and tooth enamel defects.
Defects in KRT14 are the cause of dermatopathia pigmentosa reticularis (DPR) [MIM:125595]. DPR is a rare ectodermal dysplasia characterized by lifelong persistent reticulate hyperpigmentation, noncicatricial alopecia, and nail dystrophy. -
Sequence similarities
Belongs to the intermediate filament family. -
Cellular localization
Cytoplasm. Nucleus. Expressed in both as a filamentous pattern. - Information by UniProt
-
Database links
- Entrez Gene: 3861 Human
- Omim: 148066 Human
- SwissProt: P02533 Human
- Unigene: 654380 Human
-
Alternative names
- CK 14 antibody
- CK-14 antibody
- ck14 antibody
see all
Images
-
ab192056 staining KRT14 in wild-type A431 cells (top panel) and KRT14 knockout A431 cells (bottom panel). The cells were fixed with 100% methanol (5 min) then permeabilized with 0.1% Triton X-100 for 5 minutes and then blocked with 1% BSA/10% normal goat serum/0.3M glycine in 0.1% PBS-Tween for 1h. The cells were then incubated with ab192056 at 1/100 dilution and ab195887 (Mouse monoclonal to alpha Tubulin - Alexa Fluor® 488) at 1/250 dilution overnight at 4°C. Nuclear DNA was labelled in blue with DAPI.
Image was taken with a confocal microscope (Leica-Microsystems TCS SP8). -
ab192056 staining Cytokeratin 14 in A431 cells. The cells were fixed with 100% methanol (5min), permeabilized in 0.1% Triton X-100 for 5 minutes and then blocked in 1% BSA/10% normal goat serum/0.3M glycine in 0.1% PBS-Tween for 1h. The cells were then incubated with ab192056 at a working dilution of 1 in 100 (shown in red) and ab7291 (Mouse monoclonal [DM1A] to alpha Tubulin) at 1µg/ml overnight at +4°C, followed by a further incubation at room temperature for 1h with an Alexa Fluor® 488 Goat anti-Mouse secondary (ab150117) at 2μg/ml (shown in green). Nuclear DNA was labelled in blue with DAPI.
This product gave a positive signal in 4% formaldehyde (10min) fixed HeLa cells under the same testing conditions.
Protocols
Datasheets and documents
-
SDS download
-
Datasheet download
Certificate of Compliance
References (3)
ab192056 has been referenced in 3 publications.
- Deng S et al. Ectopic JAK-STAT activation enables the transition to a stem-like and multilineage state conferring AR-targeted therapy resistance. Nat Cancer 3:1071-1087 (2022). PubMed: 36065066
- Sun S et al. Modeling human HSV infection via a vascularized immune-competent skin-on-chip platform. Nat Commun 13:5481 (2022). PubMed: 36123328
- Mi S et al. Microfluidic co-culture system for cancer migratory analysis and anti-metastatic drugs screening. Sci Rep 6:35544 (2016). ICC/IF ; Human . PubMed: 27762336